An update: cancer-associated anorexia as a treatment target.
Loss of appetite is pervasive among patients with advanced cancer. Cancer patients cite it as one of their most troubling symptoms. To date, however, palliative options remain limited. Megestrol acetate and dexamethasone provide only modest relief. Novel agents such as thalidomide, adenosine triphosphate, and other cytokine inhibitors merit further investigation.
Jatoi
A
A
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Loprinzi
C L
CL
D000818:Animals; D000855:Anorexia / Q000188:drug therapy* / Q000209:etiology; D001066:Appetite / Q000187:drug effects; D001069:Appetite Regulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004435:Eating / Q000187:drug effects; D001068:Feeding and Eating Disorders / Q000188:drug therapy; D006801:Humans; D019290:Megestrol Acetate / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D015431:Weight Loss / Q000187:drug effects*
D003533:Cyproheptadine; D003907:Dexamethasone; D019290:Megestrol Acetate